Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

217 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
KRAS mutations in non-small cell lung cancer.
Riely GJ, Marks J, Pao W. Riely GJ, et al. Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5. doi: 10.1513/pats.200809-107LC. Proc Am Thorac Soc. 2009. PMID: 19349489 Review.
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG, Varmus HE. Pao W, et al. PLoS Med. 2005 Jan;2(1):e17. doi: 10.1371/journal.pmed.0020017. Epub 2005 Jan 25. PLoS Med. 2005. PMID: 15696205 Free PMC article.
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Pao W, et al. PLoS Med. 2005 Mar;2(3):e73. doi: 10.1371/journal.pmed.0020073. Epub 2005 Feb 22. PLoS Med. 2005. PMID: 15737014 Free PMC article.
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA. Riely GJ, et al. Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44. doi: 10.1158/1078-0432.CCR-05-1846. Clin Cancer Res. 2006. PMID: 16467097 Clinical Trial.
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W, Wilson RK, Singh B, Rusch VW. Pham D, et al. J Clin Oncol. 2006 Apr 10;24(11):1700-4. doi: 10.1200/JCO.2005.04.3224. Epub 2006 Feb 27. J Clin Oncol. 2006. PMID: 16505411
Molecular on/off switch.
Milton DT, Riely GJ, Pao W, Miller VA, Kris MG, Heelan RT. Milton DT, et al. J Clin Oncol. 2006 Oct 20;24(30):4940-2. doi: 10.1200/JCO.2006.06.4410. J Clin Oncol. 2006. PMID: 17050880 No abstract available.
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W. Balak MN, et al. Clin Cancer Res. 2006 Nov 1;12(21):6494-501. doi: 10.1158/1078-0432.CCR-06-1570. Clin Cancer Res. 2006. PMID: 17085664
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy.
Riely GJ, Gadgeel S, Rothman I, Saidman B, Sabbath K, Feit K, Kris MG, Rizvi NA. Riely GJ, et al. Lung Cancer. 2007 Feb;55(2):181-5. doi: 10.1016/j.lungcan.2006.10.002. Epub 2006 Nov 7. Lung Cancer. 2007. PMID: 17092603 Clinical Trial.
Update on epidermal growth factor receptor mutations in non-small cell lung cancer.
Riely GJ, Politi KA, Miller VA, Pao W. Riely GJ, et al. Clin Cancer Res. 2006 Dec 15;12(24):7232-41. doi: 10.1158/1078-0432.CCR-06-0658. Clin Cancer Res. 2006. PMID: 17189394 Review.
217 results
Jump to page
Feedback